Impact of the 13-Valent Pneumococcal Conjugate Vaccine on the Incidence of All-cause Pneumonia in Adults Aged ≥60 Years: A Population-based, Retrospective Cohort Study

Clin Infect Dis. 2019 May 30;68(12):2117-2119. doi: 10.1093/cid/ciy993.

Abstract

In this population-based study evaluating the effectiveness of the 13-valent pneumococcal conjugate vaccine (2012-2016) to prevent all-cause pneumonia in adults ≥60 years of age, we found significant, 0.63% absolute risk and 11.9% relative risk reductions on the 3-year (2014-2016) cumulative incidences of all-cause pneumonia after vaccination.

Keywords: elderly; pneumococcal vaccination; pneumonia; prevention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Pneumococcal Vaccines / administration & dosage
  • Pneumococcal Vaccines / immunology*
  • Pneumonia, Pneumococcal / epidemiology*
  • Pneumonia, Pneumococcal / etiology
  • Pneumonia, Pneumococcal / prevention & control*
  • Population Surveillance
  • Retrospective Studies
  • Vaccination

Substances

  • 13-valent pneumococcal vaccine
  • Pneumococcal Vaccines